David Blanchard

David Blanchard

Auto-generated profile, based on publicly available information

David Blanchard

Department of Cardiac Surgery and Transplantation, Marie Lannelongue Hospital, Groupe Hospitalier Paris Saint Joseph, Le Plessis Robinson, France

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
SHSebastien Hascoet
Sebastien Hascoet
GSGrzegorz Smolka
Grzegorz Smolka
DBDavid Blanchard
David Blanchard
MKMartin Kloëckner
Martin Kloëckner
EBEric Brochet
Eric Brochet
BGBenoît Gérardin
Benoît Gérardin
Background: Transcatheter closure of a symptomatic prosthetic paravalvular leak (PVL) is feasible, but there is presently no conclusive evidence to show consistent efficacy. We aimed to identify predictors of clinical success after transcatheter PVL closure. Methods: Consecutive patients referred to 24 European centers for transcatheter PVL closure in 2017 to 2019 were included in a prospective registry ( Fermeture de Fuite ParaProthétique , FFPP). Clinical success was absence of any of the following within 1 month: re-admission for heart failure, blood transfusion, open-heart valvular surgery, and death. Results: We included 216 symptomatic patients, who underwent 238 percutaneous PVL closure procedures on the mitral (64.3%), aortic (34.0%), or tricuspid (1.7%) valve. Symptoms were heart failure, hemolytic anemia, or both in 48.9%, 7.8%, and 43.3% of patients, respectively. One, 2, and 3 leaks were treated during the same procedure in 69.6%, 26.6%, and 3.8% of patients, respectively. The PVL was pinpoint or involved 1/8 or 1/4 of the valve circumference in 18.6%, 52.4%, and 28.1% of cases, respectively. The most frequently used devices were the Vascular Plug 3, Ventricular Septal Defect Occluder, Vascular Plug 2, and Paravalvular Leak Device (45.0%, 16.6%, 14.2%, and 13.6% of cases, respectively). Successful device(s) implantation with leak reduction to ≤grade 2 was obtained in 85.0% of mitral and 91.4% of aortic procedures, respectively ( P =0.164); with major periprocedural adverse event rates of 3.3% and 1.2%, respectively ( P =0.371); and clinical success rates of 70.3% and 88.0%, respectively ( P =0.004). By multivariate analysis, technical failure, mechanical valve, and hemolytic anemia were independently associated with absence of clinical success (odds ratios [95% CIs], 7.7 [2.0–25.0]; P= 0.002; 3.6 [1.1–11.1]; P =0.036; and 3.7 [1.2–11.9]; P =0.025; respectively). Conclusions: Transcatheter PVL closure is efficient and safe in symptomatic patients but is associated with a lower clinical success rate in patients with hemolysis and/or a mechanical valve. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT05089136

21 August 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DBDorothee Brunet
Dorothee Brunet
SVSimon Dang Van
Simon Dang Van
MKMartin Kloeckner
Martin Kloeckner
DBDavid Blanchard
David Blanchard
JGJulien Guihaire
Julien Guihaire

8 August 2024 in Annales de Cardiologie et d'Angéiologie
Verified
Journal Article
Closed access
BGB. Gérardin
B. Gérardin
SHS. Hascoët
S. Hascoët
JAJn. Andarelli
Jn. Andarelli
CBC. Batteux
C. Batteux
GAG. Albenque
G. Albenque
PBP. Brenot
P. Brenot